SGLT2-inhibition and myocardial infarction size in patients with type 2 diabetes mellitus- Insights from an acute cardiovascular care center.

ABSTRACT:

Aims

This study aimed to assess the association between myocardial infarction (MI) size and clinical outcome with ongoing Sodium-glucose-cotransporter-2 inhibitor (SGLT2-i) use.

Methods and results

In this retrospective single-center cohort study 681 patients with MI and diabetes mellitus type 2 (T2DM) treated with percutaneous coronary intervention (PCI) between November 2015 and December 2023 were included. 105 patients received ongoing SGLT2-i therapy and 576 were taking other glucose-lowering medication at the time of admission. The primary outcome was the size of MI. MI size was determined by the peak high-sensitive troponinT (hs-TnT x ULN [upper limit of normal]) normalized on the endangered myocardial area (EMA). No significant statistical differences were observed in

SUBMITTER: Bojti I 

PROVIDER: S-EPMC12317468 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature